Join to View Full Profile
1600 E Jefferson StSte A1Seattle, WA 98122
Phone+1 206-320-2200
Fax+1 206-320-2560
Dr. Qian is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 2007 - 2010
SSM St Mary's Hospital-St LouisInternship, Internal Medicine, 2006 - 2007
Shanghai Jiao Tong University School of MedicineClass of 1993
Certifications & Licensure
WA State Medical License 2012 - 2027
MO State Medical License Active through 2013
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Vitamin D Supplementation in Multiple Sclerosis Start of enrollment: 2012 Mar 01
Publications & Presentations
PubMed
- Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.Hans-Peter Hartung, Derrick Robertson, Lawrence Steinman, Douglas L Arnold, Peiqing Qian
Neurology and Therapy. 2026-06-01 - Evaluation of Documented Infections by Provider Specialty in Patients with Multiple Sclerosis Receiving Disease-Modifying Therapies: A Claims Database Analysis.Peiqing Qian, Jenna Brunn, Wennifer Giglio, Kelly Holmes, Elijah Lackey
Advances in Therapy. 2026-05-19 - 1 citationsFive Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.Bruce A C Cree, Edward Fox, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian
JAMA Neurology. 2026-04-01
Press Mentions
ACTRIMS 2023: Most on Briumvi Show No MS Activity After 6 MonthsMarch 2nd, 2023- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (Ublituximab) in Multiple Sclerosis to Be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumFebruary 14th, 2023
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
